ADA Updates Standards of Care to Include Teplizumab for Delaying T1D, Reflect Emphasis on NAFLD

At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.

Related Keywords

United States ,Aleppo ,Lab ,Syria ,American ,Campbellp Teplizumab ,Robert Gabbay ,Nuha El Sayed ,Linkedin Robert Gabbay ,Practice Committee ,American Diabetes Association ,American Diabetes Association Releasesa Guideline ,Drug Administration ,American Diabetes Association Releases Updates ,Nonalcoholic Fatty Liver Disease ,Scientific Sessions ,Delaying Onset ,Associated Comorbidities ,Professional Practice Committee ,Nonalcoholic Fatty Liver ,Diabetes Association ,Diabetes Association Releases Updates ,Diabetes Association Releases ,Guideline Update ,Non Alcoholic Fatty Liver Disease ,Diabetes Care ,Published November ,Medical Evaluation ,